Last reviewed · How we verify
Human serum albumin infusion 4%
Human serum albumin infusion 4% is a Small molecule drug developed by University Hospital, Strasbourg, France. It is currently FDA-approved. Also known as: VIALEBEX* 4%.
At a glance
| Generic name | Human serum albumin infusion 4% |
|---|---|
| Also known as | VIALEBEX* 4% |
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Belimumab With Rituximab for Primary Membranous Nephropathy (PHASE2)
- Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites (PHASE3)
- Intravenous Immunoglobulin and Prednisolone for RPL After ART. (PHASE2)
- Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock (NA)
- Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) (NA)
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
- Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer (NA)
- QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human serum albumin infusion 4% CI brief — competitive landscape report
- Human serum albumin infusion 4% updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI
Frequently asked questions about Human serum albumin infusion 4%
What is Human serum albumin infusion 4%?
Human serum albumin infusion 4% is a Small molecule drug developed by University Hospital, Strasbourg, France.
Who makes Human serum albumin infusion 4%?
Human serum albumin infusion 4% is developed and marketed by University Hospital, Strasbourg, France (see full University Hospital, Strasbourg, France pipeline at /company/university-hospital-strasbourg-france).
Is Human serum albumin infusion 4% also known as anything else?
Human serum albumin infusion 4% is also known as VIALEBEX* 4%.
What development phase is Human serum albumin infusion 4% in?
Human serum albumin infusion 4% is FDA-approved (marketed).
Related
- Manufacturer: University Hospital, Strasbourg, France — full pipeline
- Also known as: VIALEBEX* 4%
- Compare: Human serum albumin infusion 4% vs similar drugs
- Pricing: Human serum albumin infusion 4% cost, discount & access